Detailed Information
Cited 2 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study.
- Authors
- Albiges, L[Albiges, Laurence]; Beckermann, K[Beckermann, Katy]; Miller, WH[Miller, Wilson H.]; Goh, JC[Goh, Jeffrey C.]; Gajate, P[Gajate, Pablo]; Harris, CA[Harris, Carole A.]; Suarez, C[Suarez, Cristina]; Peer, A[Peer, Avivit]; Park, SH[Park, Se Hoon]; Stadler, WM[Stadler, Walter Michael]; Weickhardt, AJ[Weickhardt, Andrew James]; Faust, G[Faust, Guy]; Fong, PCC[Fong, Peter C. C.]; Waddell, T[Waddell, Tom]; Venugopal, B[Venugopal, Balaji]; Yin, L[Yin, Lina]; Wang, D[Wang, Ding]; Perini, RF[Perini, Rodolfo F.]; Powles, T[Powles, Thomas]
- Issue Date
- 1-Jun-2023
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.41, no.16
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 41
- Number
- 16
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.